QPS provides critical support and partnership to the pharmaceutical and biotech industries. Please rest assured that we remain open for business to support these essential industries. QPS is committed to keeping our Bioanalysis, Translational Medicine, Neuropharmacology, DMPK and Toxicology laboratories in the USA, Europe and Asia, operating at 100% to support COVID-19 clinical trials, as well as research and development of new drug therapies and vaccines. With multiple phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to fast-track first-in-man and Phase I/II safety studies for compounds in development to combat the novel coronavirus. Furthermore, as a full service CRO QPS has all clinical research capabilities as well as efficient access to specialized sites and experienced investigators with the capability to run COVID-19 patient trials in EU, US and Asia. Of course, QPS will continue to follow the guidelines put forth by the CDC, WHO, ECDC, local and state health departments.
We are currently in the midst of the greatest global health crisis in decades: the COVID-19 pandemic. As this novel coronavirus affects communities around the world, there is an increasingly urgent demand for available and accurate testing services, effective drug therapies, and a COVID-19 vaccine. With its proven quality standards, technical expertise, turnkey laboratories, and decades of experience, QPS is well prepared to support your novel coronavirus or COVID-19-related project.
Our team is prepared to analyze clinical trial samples that are known to be contaminated, or could be contaminated, with the novel coronavirus at the access-restricted bioanalysis lab on our campus in Newark, Delaware. We can quickly process samples and deliver results to help drug companies evaluate employees for COVID-19 antibodies, assess the effectiveness of potential vaccines and drug therapies, and provide additional bioanalytical support as needed to accelerate drug development programs related to the novel coronavirus.
With multiple Phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to fast-track first-in-man and Phase I/II safety studies for compounds in development to combat the novel coronavirus. Furthermore, as a full service CRO QPS has all clinical research capabilities as well as efficient access to specialized sites and experienced investigators with the capability to run COVID-19 patient trials in EU, US and Asia.
QPS has decades of experience assisting pharmaceutical companies slow the progress of viral outbreaks, and we are committed to supporting the life sciences community in fighting COVID-19. Due to the catastrophic reach of this pandemic, a scientific breakthrough is direly needed, and our team is ready to move your clinical trials, serological assays, and vaccine and drug development programs toward a regulatory submission.
Clinical Study Start Up Guide:
Global QPS clinical study sites are up and running, taking all appropriate precautions. Read all about our plans in this brochure.
Please use the form below to submit your request for preclinical or clinical drug development and testing services related to the novel coronavirus or COVID-19.
Contact Us Today!
QPS is ready to support your novel coronavirus or COVID-19-related project.
More Information About COVID-19
The spread of COVID-19 is impacting every facet of the pharmaceutical industry, including planned and ongoing clinical trials. Recognizing that the coronavirus presents challenges to protocol-specified procedures, the Food and Drug Administration (FDA) has published guidelines regarding the conduct of clinical trials during this unprecedented time. To learn more about these guidelines, please visit our page Clinical Trials: Coronavirus Impact and FDA Guidelines.
Today, the FDA issued a new video resource explaining the different categories of tests in the fight against COVID-19: diagnostic tests and antibody tests. As the video explains, diagnostic tests can tell if the tested person currently is infected. Antibody or serology tests detect if the person’s blood contains antibodies to coronavirus. The body produces antibodies when one becomes infected by the virus, and they help the immune system fight off the infection. If an antibody test finds antibodies in the blood, it likely means the person has been previously infected with the virus. Antibody tests do not detect whether a person is currently infected and should not be used to diagnose a current COVID-19 infection. The results from antibody tests can help us better understand questions about exposure to COVID-19.